Chloe Shay

Chloe Shay

Auto-generated profile, based on publicly available information

Chloe Shay

Wallace H. Coulter Department of Biomedical Engineering, Georgia Institute of Technology and Emory, University, Atlanta, Georgia

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 July 2018 in Journal of Molecular Medicine
Verified
Journal Article
Closed access
PDF file
LGLixia Gao
Lixia Gao
XZXiangdong Zhao
Xiangdong Zhao
LLLiwei Lang
Liwei Lang
CSChloe Shay
Chloe Shay
Andrew YeudallAndrew Yeudall
Andrew Yeudall
Yong TengYong Teng
Yong Teng

19 April 2023 in Cancer Research Communications
Verified
Journal Article
Open access
PDF file
LLLiwei Lang
Liwei Lang
FCFanghui Chen
Fanghui Chen
Yamin LiYamin Li
Yamin Li
CSChloe Shay
Chloe Shay
FYFan Yang
Fan Yang
Yong TengYong Teng
Yong Teng
Radiotherapy plays an essential role in the treatment of head and neck squamous cell carcinoma (HNSCC), yet radioresistance remains a major barrier to therapeutic efficacy. A better understanding of the predominant pathways determining radiotherapy response could help develop mechanism-informed therapies to improve cancer management. Here we report that radioresistant HNSCC cells exhibit increased tumor aggressiveness. Using unbiased proteome profiler antibody arrays, we identify that upregulation of c-Met phosphorylation is one of the critical mechanisms for radioresistance in HNSCC cells. We further uncover that radioresistance-associated HNSCC aggressiveness is effectively exacerbated by c-Met but is suppressed by its genetic knockdown and pharmacologic inactivation. Mechanistically, the resulting upregulation of c-Met promotes elevated expression of plexin domain containing 2 (PLXDC2) through activating ERK1/2-ELK1 signaling, which in turn modulates cancer cell plasticity by epithelial–mesenchymal transition (EMT) induction and enrichment of the cancer stem cell (CSC) subpopulation, leading to resistance of HNSCC cells to radiotherapy. Depletion of PLXDC2 overcomes c-Met–mediated radioresistance through reversing the EMT progress and blunting the self-renewal capacity of CSCs. Therapeutically, the addition of SU11274, a selective and potent c-Met inhibitor, to radiation induces tumor shrinkage and limits tumor metastasis to lymph nodes in an orthotopic mouse model. Collectively, these significant findings not only demonstrate a novel mechanism underpinning radioresistance-associated aggressiveness but also provide a possible therapeutic strategy to target radioresistance in patients with HNSCC. Significance: This work provides novel insights into c-Met-PLXDC2 signaling in radioresistance-associated aggressiveness and suggests a new mechanism-informed therapeutic strategy to overcome failure of radiotherapy in patients with HNSCC.

19 April 2023
Verified
Other
Open access
LLLiwei Lang
Liwei Lang
FCFanghui Chen
Fanghui Chen
Yamin LiYamin Li
Yamin Li
CSChloe Shay
Chloe Shay
FYFan Yang
Fan Yang
Yong TengYong Teng
Yong Teng
Validation the expression levels of top five most upregulated genes (identified from RNA-seq) in radioresistant CAL27 (A) and HN6 (B) cells using qRT-PCR. *p<0.05; **p<0.01.

19 April 2023
Verified
Other
Open access
LLLiwei Lang
Liwei Lang
FCFanghui Chen
Fanghui Chen
Yamin LiYamin Li
Yamin Li
CSChloe Shay
Chloe Shay
FYFan Yang
Fan Yang
Yong TengYong Teng
Yong Teng
Validation the expression levels of top five most upregulated genes (identified from RNA-seq) in radioresistant CAL27 (A) and HN6 (B) cells using qRT-PCR. *p<0.05; **p<0.01.

19 April 2023
Verified
Other
Open access
LLLiwei Lang
Liwei Lang
FCFanghui Chen
Fanghui Chen
Yamin LiYamin Li
Yamin Li
CSChloe Shay
Chloe Shay
FYFan Yang
Fan Yang
Yong TengYong Teng
Yong Teng
Inhibitory effect of three c-Met inhibitors on c-Met phosphorylation in CAL27 cells. CAL27 cells were treated with 2.5 µM SU11274, foretinib or crizotinib for 24 hours, followed by Western blotting analysis.